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Abstract
Background: Feline herpesvirus 1 (FHV-1) is a common cause of respiratory and ocular disease
in cats. Especially in young kittens that have not yet reached the age of vaccination, but already lost
maternal immunity, severe disease may occur. Therefore, there is a need for an effective antiviral
treatment. In the present study, the efficacy of six antiviral drugs, i.e. acyclovir, ganciclovir,
cidofovir, foscarnet, adefovir and 9-(2-phosphonylmethoxyethyl)-2, 6-diaminopurine (PMEDAP),
against FHV-1 was compared in Crandell-Rees feline kidney (CRFK) cells using reduction in plaque
number and plaque size as parameters.
Results: The capacity to reduce the number of plaques was most pronounced for ganciclovir,
PMEDAP and cidofovir. IC50 (NUMBER) values were 3.2 µg/ml (12.5 µM), 4.8 µg/ml (14.3 µM) and 6µg/ml (21.5 µM), respectively. Adefovir and foscarnet were intermediately efficient with an IC50
(NUMBER) of 20 µg/ml (73.2 µM) and 27 µg/ml (140.6 µM), respectively. Acyclovir was least efficient
(IC50 (NUMBER) of 56 µg/ml or 248.7 µM). All antiviral drugs were able to significantly reduce plaque
size when compared with the untreated control. As observed for the reduction in plaque number,
ganciclovir, PMEDAP and cidofovir were most potent in reducing plaque size. IC50 (SIZE) values were
0.4 µg/ml (1.7 µM), 0.9 µg/ml (2.7 µM) and 0.2 µg/ml (0.7 µM), respectively. Adefovir and foscarnet
were intermediately potent, with an IC50 (SIZE) of 4 µg/ml (14.6 µM) and 7 µg/ml (36.4 µM),
respectively. Acyclovir was least potent (IC50 (SIZE) of 15 µg/ml or 66.6 µM). The results
demonstrate that the IC50 (SIZE) values were notably lower than the IC50 (NUMBER) values. The most
remarkable effect was observed for cidofovir and ganciclovir. None of the products were toxic for
CRFK cells at antiviral concentrations.
Conclusion: In conclusion, measuring reduction in plaque number and plaque size are two
valuable and complementary means of assessing the efficacy of an antiviral drug. By using these
parameters for six selected antiviral drugs, we found that ganciclovir, PMEDAP, and cidofovir are
the most potent inhibitors of FHV-1 replication in CRFK cells. Therefore, they may be valuable
candidates for the treatment of FHV-1 infection in cats.
Background
Feline herpesvirus 1 (FHV-1), an Alphaherpesvirus, is one
of the most common viruses among cats [1-3]. Infection
is associated with respiratory disorders and ocular disease,
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keratoconjunctivitis and, ultimately, loss of sight [4,5].
The severity of clinical symptoms induced by FHV-1 infec-
tion can be reduced by vaccination [6,7]. However, espe-
cially in young kittens that have not yet reached the age of
vaccination, but already lost maternal immunity, severe
disease may still occur. Once these kittens have developed
lesions, recurrent disease and virus excretion may occur
upon reactivation at later age [8]. In order to control dis-
ease in these cases, treatment with an effective antiviral
drug would be helpful.
Several antiviral drugs have already been tested for their
efficacy to inhibit FHV-1 replication by means of a classi-
cal plaque number reduction assay. Based on the IC50 or
concentration needed to reduce plaque number with 50
%, especially the acyclic nucleoside phosphonate (ANP)
(S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine
(HPMPA) [9] seems very efficient. Also, the ANP cidofovir
[10] as well as the nucleoside analogues ganciclovir, pen-
ciclovir [10], idoxuridine [10,11], trifluridine [9,11] and
vidarabine [11] are efficient in reducing the number of
FHV-1-induced plaques in vitro. Acyclovir and foscarnet,
although of proven value against human herpesviruses,
have low efficacy against the formation of plaques by
FHV-1 [9-11].
Besides by reducing the number of plaques, as described
above, antiviral agents may also exert an effect by reducing
the size of herpesvirus-induced plaques [12,13]. Reduc-
tion in plaque size may be a potential parameter for the
ability of an antiviral agent to restrict the size of macro-
scopic lesions in vivo [12]. Up till now, no studies have
addressed the efficacy of antiviral agents to limit the size
of FHV-1-induced plaques.
The aim of the present study was to compare the efficacy
of six antiviral drugs against FHV-1 in vitro. Parameters
used to measure efficacy were the ability to limit FHV-1-
induced plaque number (expressed as inhibitory concen-
tration or IC (NUMBER)) as well as plaque size (expressed as
IC (SIZE)) in Crandell-Rees feline kidney (CRFK) cells.
Results
Effect of the antiviral drugs on plaque number
Figure 1 presents the dose-response curves regarding the
inhibitory effect of each antiviral drug on plaque number
(solid lines). The IC50 (NUMBER) values were extrapolated
from the curves and are presented in Table 1. The capacity
to reduce the number of plaques was most pronounced
for ganciclovir, PMEDAP and cidofovir. Adefovir and
foscarnet were intermediately efficient. Acyclovir was least
efficient.
No significant variation in plaque number was observed
between FHV-1-inoculated cells incubated with various
concentrations of Roswell Park Memorial Institute
(RPMI)-1640 medium and the untreated control (LSD,
95% confidence interval).
Effect of the antiviral drugs on plaque size
It is known that marked differences may occur in plaque
size when FHV-1 is grown in vitro. Therefore, data
obtained in the plaque size assay were subjected to an F-
test to examine whether the variation in plaque size
between samples was significantly different from the vari-
ation in plaque size within a sample (95% confidence
interval). Or, in other words, the F-test was used to answer
the question whether variation in plaque size was merely
an artefact or whether it was related to the use of antiviral
drugs. It was found that all antiviral drugs exhibited a sig-
nificant effect on plaque size (significance ≤ 0.001). Using
a post-hoc LSD-test it was demonstrated that the reduc-
tion in plaque size was significant for all drugs at all con-
centrations when compared with the untreated control
(95% confidence interval). The variation in plaque size
observed in FHV-1-inoculated cells incubated with vari-
ous concentrations of RPMI was not significantly different
from the variation in plaque size observed in the
untreated control (F-test, 95% confidence interval).
Figure 1 presents the dose-response curves regarding the
inhibitory effect of each antiviral drug on plaque size
(dashed lines). The IC50 (SIZE) values were extrapolated
from the curves and are presented in Table 1. As observed
for the reduction in plaque number, ganciclovir, PMEDAP
and cidofovir were most potent in reducing plaque size.
Adefovir and foscarnet were intermediately potent and
acyclovir was least potent. For all six drugs, the IC50 (SIZE)
was notably lower than the IC50 (NUMBER) (Figure 1; Table
1). The most remarkable effect was observed for cidofovir
and ganciclovir.
Effect of the antiviral drugs on the viability of CRFK cells
It was found that when CRFK cells were cultivated in the
presence of 2% RPMI or more, that the relative viability of
the cells was significantly lower in comparison with
untreated CRFK cells incubated with complete medium
(LSD, 95% confidence interval). In order to determine
whether the antiviral products exerted a cytotoxic effect
we, therefore, compared the mean relative viability of
CRFK cells incubated with antiviral products with the
mean relative viability of CRFK cells incubated with the
corresponding concentration of RPMI (t-test, 95% confi-
dence interval). Acyclovir exerted no significant effect on
the viability of CRFK cells up till a concentration of 500
µg/ml (2220.2 µM), ganciclovir up till a concentration of
1000 µg/ml (3918.5 µM), cidofovir up till a concentration
of 160 µg/ml (573.1 µM), foscarnet up till a concentrationPage 2 of 7
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Activity of six antiviral drugs against feline herpesvirus 1Figure 1
Activity of six antiviral drugs against feline herpesvirus 1. Dose-response curves are shown representing the activity of 
six antiviral drugs to reduce the number (solid line) and size (dashed line) of feline herpesvirus 1-induced plaques in Crandell-
Rees feline kidney cells. Data are presented as the mean value of three independent experiments + standard deviation.
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tion of 160 µg/ml (585.7 µM) and PMEDAP up till a con-
centration of 160 µg/ml (476.6 µM). These
concentrations amply exceeded the IC100 (NUMBER) and the
IC100 (SIZE) for all drugs (Figure 1), demonstrating that
none of the products were toxic for CRFK cells at antiviral
concentrations.
Discussion
Over the years, an impressive array of antiviral agents has
been developed for the treatment of human herpesvirus
infections [14]. Many of these agents have already been
studied for their efficacy against FHV-1 [15,16]. In the
present study the efficacy of a selection of six antiviral
drugs against FHV-1 was compared in CRFK cells using
two different parameters, i.e. reduction in plaque number
and reduction in plaque size.
Our study demonstrates that the efficacy of the drugs to
reduce the number of plaques can be ranked as follows:
ganciclovir (relative antiviral efficacy 1) → PMEDAP (rel-
ative antiviral efficacy 1.1) → cidofovir (relative antiviral
efficacy 1.7) → adefovir (relative antiviral efficacy 5.9) →
foscarnet (relative antiviral efficacy 11.2) → acyclovir (rel-
ative antiviral efficacy 19.9). The results for ganciclovir
and cidofovir are similar to those obtained by Maggs and
Clarke [10], who compared the ability of four antiviral
drugs to reduce the number of plaques in CRFK cells. They
found an IC50 (NUMBER) of 5.2 µM for ganciclovir and of 11µM for cidovir (or a relative antiviral efficacy of 1 and 2.1,
respectively). Concerning the activity of foscarnet and acy-
clovir, our results are slightly different from those
obtained by Maggs and Clarke [10]. The latter authors
found a lower activity for foscarnet (IC50 (NUMBER) 232.9µM or relative antiviral efficacy 44.8) and a higher activity
for acyclovir (IC50 (NUMBER) 57.9 µM or relative antiviral
efficacy 11.1). Also, other authors obtained variable
results on the activity of acyclovir against FHV-1, with IC50
(NUMBER) values ranging from 44.4 to 109 µM [9,11,17]. A
potential explanation for the observed variation may be
related to the virus strain. Indeed, in a comparative study
of Nasisse et al. [11], the IC50 (NUMBER) for acyclovir in
CRFK cells varied almost 2-fold depending on the FHV-1
strain used. Also, there may be inter-test variation
involved. While both testing the activity of acyclovir
against FHV-1 strain 727 on CRFK cells, Nasisse et al. [11]
reported a markedly higher IC50 (NUMBER) (109 µM) than
Maggs and Clarke [10] (57.9 µM).
Antiviral agents not only reduce the number of herpesvi-
rus-induced plaques, they also contribute in the reduction
of plaque size [12,13]. Our study is the first that addressed
the ability of antiviral agents to reduce the size of FHV-1-
induced plaques. Ranking the drugs following their rela-
tive ability to reduce plaque size resulted in cidofovir (1)
→ ganciclovir (2.4) → PMEDAP (3.9) → adefovir (20.9)
→ foscarnet (52) → acyclovir (95.1), which is an almost
exactly equivalent ranking as that for plaque number data.
The latter demonstrates that measuring plaque size is a
useful and complementary means of assessing antiviral
efficacy.
Interestingly, for all six drugs it was found that the concen-
tration needed to reduce plaque size was notably lower
than that needed to reduce plaque number (Figure 1;
Table 1). The most remarkable effect was observed for
cidofovir. Its IC50 (SIZE) was 30-times lower than its IC50
(NUMBER). For ganciclovir, the IC50 (SIZE) was 8-times lower.
For the other four drugs, a 4 to 5-times lower concentra-
tion was required to reduce plaque size with 50% when
compared with the IC50 (NUMBER). The relevance of this
finding in view of protection of cats against FHV-1-
induced disease remains to be determined. However, as
already speculated by Mikloska and Cunningham [12],
reduction of plaque size in vitro may be a potential param-
eter for the ability of an antiviral agent to restrict the size
of virus-induced lesions in vivo.
The ability of adefovir to inhibit FHV-1 replication was
found to differ markedly from PMEDAP. This seems
rather surprising since both drugs, which belong to the
class of acyclic nucleoside phosphonates, are closely
Table 1: The effect of selected antiviral drugs on number and size of feline herpesvirus 1-induced plaques in Crandell-Rees feline kidney 
cells
Antiviral drug IC50 (NUMBER) IC50 (SIZE)
Acyclovir 56 µg/ml (248.7 µM) 15 µg/ml (66.6 µM)
Ganciclovir 3.2 µg/ml (12.5 µM) 0.4 µg/ml (1.7 µM)
Cidofovir 6 µg/ml (21.5 µM) 0.2 µg/ml (0.7 µM)
Foscarnet 27 µg/ml (140.6 µM) 7 µg/ml (36.4 µM)
Adefovir 20 µg/ml (73.2 µM) 4 µg/ml (14.6 µM)
PMEDAP 4.8 µg/ml (14.3 µM) 0.9 µg/ml (2.7 µM)
IC50 (NUMBER): concentration of a product required to reduce the plaque number with 50 % in comparison with untreated cells
IC50 (SIZE): concentration of a product required to reduce the plaque size with 50% in comparison with untreated cells
PMEDAP: 9-[2-phosphonylmethoxyethyl]-2, 6-diaminopurinePage 4 of 7
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on the inhibition of viral DNA polymerase by the corre-
sponding active diphosphate derivatives. A possible
explanation could be a difference in uptake of the drugs
by CRFK cells. However, Kramata and Downey [18] found
that cellular uptake did not significantly differ between
adefovir and PMEDAP in a human T-lymphoblastoid cell
line CCRF-CEM. Alternatively, viral DNA polymerase may
have a higher sensitivity for the PMEDAP diphosphate
derivatives than for adefovir diphosphate derivatives, sim-
ilar as described for cellular DNA polymerase [18]. Also,
there may be a variation in intracellular stability of each
drug metabolite as observed for other antiviral drugs
[19,20]. It seems unlikely that the efficiency of phosphor-
ylation by cellular enzymes and, consequently, the
amounts of the active diphosphates differ. For both drugs,
phosphorylation is catalyzed by mitochondrial and
cytosolic isoenzymes of AMP kinase [21,22].
None of the products were toxic for CRFK cells at antiviral
concentrations. However, the results of the cytotoxicity
assay cannot simply be extrapolated to the cat itself, as
sensitivity of host cells to a certain drug may differ from
those of a continuous cell line. For example, while we
were unable to detect a significant effect of cidofovir on
the viability of CRFK cells up to a concentration of 160 µg/
ml, Sandmeyer and colleagues [23] reported cytotoxic
effects at a concentration of 50 µg/ml in a primary cell cul-
ture of feline corneal epithelial cells. Also, adefovir exerted
no cytotoxic effects in our in vitro study, but when applied
in cats for the treatment of feline infectious peritonitis
virus [24] or feline leukaemia virus [25], severe haemato-
logical side effects were observed. This highlights the need
for extensive safety studies in the cat.
Conclusion
From our study, it can be concluded that measuring reduc-
tion in plaque number and plaque size are two valuable
and complementary means of assessing the efficacy of an
antiviral drug. By using these parameters for six selected
antiviral drugs, we found that ganciclovir, PMEDAP, and
cidofovir are most potent inhibitors of FHV-1 replication
in CRFK cells. Therefore, they may be valuable candidates
for the treatment of FHV-1 infection in cats.
Methods
Cells and virus
CRFK cells (CCL-94, ATCC, Manassas, VA, USA) were
grown and maintained in complete medium consisting of
Minimum Essential Medium (MEM) (Invitrogen, Merel-
beke, Belgium) supplemented with 5 % fetal bovine
serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 0.1
mg/ml kanamycin, 0.3 mg/ml glutamin and 1 mg/ml lac-
talbumin hydrolysate. Cells were trypsinized once a week.
The Belgian strain 94K49 was used for inoculation. This
strain was isolated from a cat with respiratory disorders
and identified as FHV-1 using monoclonal antibodies
22C12, 22F4 and 41G4 against FHV-1 glycoprotein gC,
gB, and gD, respectively [26]. Virus used for inoculation
was at the 3rd passage on CRFK cells.
Antiviral drugs
Acyclovir, ganciclovir, adefovir and PMEDAP were dis-
solved in RPMI-1640 medium (Invitrogen, Merelbeke,
Belgium) at a concentration of 1 mg/ml. Cidofovir and
foscarnet were dissolved in RPMI-1640 at a concentration
of 2 mg/ml. Subsequently, all drugs were filtered through
a 0.45 µm filter to obtain a sterile solution and stored at
4°C. Before use, acyclovir was adapted to room tempera-
ture to re-dissolve possible precipitates.
Antiviral assays
CRFK-cells were grown to confluency in 24-well culture
plates (Nunc A/S, Roskilde, Denmark) in complete
medium at 37°C and 5 % CO2. Then, medium was
removed and cells in each well were inoculated with 40
PFU of FHV-1 in 200 µl of complete medium. After 1 h
incubation at 37°C and 5 % CO2, cells were washed twice
with MEM. Afterwards, they were overlaid with medium
containing carboxymethylcellulose (CMC) (0.94 %) and
various concentrations of antiviral drugs. First, a broad
range of concentrations was tested to allow a preliminary
estimation of the antiviral efficacy. Then, final concentra-
tions were chosen, as indicated in Figure 1. FHV-1-inocu-
lated cells incubated with CMC and complete medium
without antiviral drugs were included as an untreated con-
trol. Additionally, FHV-1-inoculated cells incubated with
CMC and various concentrations of RPMI, ranging from
0.25 % to 20 % in complete medium, were included to
test whether RPMI influenced plaque formation by FHV-
1.
At 72 hours post inoculation, overlay medium was
removed, cells were rinsed with PBS and, consecutively,
fixed with paraformaldehyde 4 % and methanol + 1 %
H2O2. An immunoperoxidase monolayer assay (IPMA)
was performed based on van der Meulen et al. [27].
Briefly, cells were incubated with a mixture of mono-
clonal antibodies 22C12, 22F4 and 41G4 against FHV-1
glycoprotein gC, gB, and gD, respectively [26] for 1 h at
37°C. After three washing steps, peroxidase-labelled goat
anti-mouse IgG (Molecular Probes) were added for 1 h at
37°C. Following three additional washing steps, substrate
solution of 3-amino-9-ethylcarbazole in 0.05 M acetate
buffer with 0.05 % hydrogen peroxide was added. Cells
were incubated for 10 minutes at 37°C and then, sub-
strate solution was replaced with acetate buffer to block
enzymatic staining.Page 5 of 7
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each concentration of antiviral drug, for each concentra-
tion of RPMI and for untreated control samples using
light microscopy (Olympus IX50). The inhibitory effect of
the antiviral drugs on plaque number was calculated by
following formula:
The minimal concentration of each product required to
reduce the plaque number with 50 % (IC50 (NUMBER)) was
hand-calculated from the dose-response curves generated
from the data.
The size of FHV-1-induced plaques for each concentration
of antiviral drug, for each concentration of RPMI and for
untreated control samples was determined as follows.
Plaques were photographed using light microscopy
(Olympus IX50) and a digital camera (Sony Progressive
3CCD), attached to a Macintosh computer. Plaques were
randomly selected in each sample and the number
counted varied between a minimum of 3 and a maximum
of 17 (mean number counted per sample was 10.4 ± 2.5).
Then, the size of each of the plaques was determined in
pixels using Scion 1.63 (National Institutes of Health)
and, finally, the mean size per sample was calculated. The
inhibitory effect of the antiviral drugs on plaque size was
subsequently calculated by following formula:
The minimal concentration of each product required to
reduce the plaque size with 50 % (IC50 (SIZE)) was hand-
calculated from the dose-response curves generated from
the data.
For each experiment, three independent replicates were
performed.
Cytotoxicity assay
In order to determine whether the antiviral drugs exerted
a toxic effect on CFRK cells, a neutral red assay was per-
formed. This assay is based on the incorporation of the
supravital dye neutral red into living cells. In brief, CRFK-
cells were grown to confluency in 96-well culture plates
(Nunc A/S, Roskilde, Denmark) in complete medium at
37°C and 5 % CO2. Then, medium was removed, cells
were incubated with various concentrations of antiviral
drugs ranging from 5 to 500 µg/ml in medium and cul-
tured for 72 h at 37°C and 5 % CO2. Cells incubated for
72 h with complete medium lacking antiviral drugs were
included as viable controls. Cells successively incubated
with complete medium for 70 h and distilled water for 2
h were included as non-viable controls. Additionally, cells
incubated for 72 h with various concentrations of RPMI,
ranging from 0.25% to 50% in complete medium, were
included to test whether RPMI influenced the viability of
CRFK cells.
After incubation, 50 µl of neutral red solution (0.1% in
distilled water) was added to each well and plates were
incubated at 37°C and 5% CO2 for 1 h. Then, cells were
rinsed with phosphate-buffered salt solution and air-dried
at room temperature for 1 h. Finally, 50 µl of SDS (10%
in distilled water) and 100 µl HC1 (0.2 M) were added
and plates were shaken for 15 sec. Absorbance was meas-
ured on a Multiskan RC (Thermo Labsystems) using a
492-nm filter. Viability of cells was calculated by follow-
ing formula:
where ODt is the absorbency of cells incubated with anti-
viral drugs or RPMI, ODd the absorbency of the non-via-
ble cell control and ODc the absorbency of the viable cell
control, respectively.
For each concentration of antiviral drug, for each concen-
tration of RPMI and for control samples, eight wells were
tested per experiment. Three independent replicates of
each experiment were performed.
Statistical analysis
Statistical analysis was based on analysis of variance
(ANOVA) using SPSS (SPSS Inc., Chicago, Illinois, USA).
Abbreviations
ANOVA: analysis of variance
ANP: acyclic nucleoside phosphonate
CMC: carboxymethylcellulose
CRFK: Crandell-Rees feline kidney
FHV-1: feline herpesvirus 1
HPMPA: (S)-9-(3-hydroxy-2-phosphonylmethoxypro-
pyl)adenine
IPMA: immunoperoxidase monolayer assay
MEM: Minimum Essential Medium
PMEDAP: 9-(2-phosphonylmethoxyethyl)-2,6-diami-
nopurine
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